Gilead (GILD) Stock May Trade At A 47% Discount Following Raised Guidance

Gilead Sciences has delivered a very strong run over the past few years, which puts a bright spotlight on whether the current share price lines up with the cash the business is expected to generate. With the stock now trading at US$170.68, the key issue for investors is how that price stacks up against what its cash flows can reasonably support over time.

• Over the last 5 years the stock has returned 209.2%, which raises the question of how much of that gain is grounded in the underlying cash generation of the business.
• Recent updates around Gilead’s HIV franchise, oncology pipeline and acquisitions, along with both growth opportunities and known pricing headwinds, can shape expectations for future cash flows and the timing of those inflows.
• Prefer to judge Gilead Sciences on sales? See what Gilead Sciences's 6.8x P/S says about the price.

The stock's next move may depend on whether that current market price is fully supported by the intrinsic value suggested by its cash flows.

If you want more ideas with a similar cash flow lens to Gilead Sciences, a focused stock screen is a helpful next step. You can start with 36 high quality undervalued stocks.

Does Gilead Sciences Look Undervalued on Cash Flow?

The Discounted Cash Flow (DCF) model here relies on Gilead Sciences continuing to turn strong free cash generation into value for shareholders. Latest twelve month free cash flow sits around $13.8b, and the forecast path assumes this cash pool grows over time rather than shrinking.

Projected future free cash flow in the model edges higher into the 2030s, which fits a business leaning on a large HIV franchise while investing heavily in oncology and inflammation. Because the DCF output sits substantially above the current share price of US$170.68, the market price appears more cautious about how durable those cash flows will be. The raised HIV guidance and oncology momentum reported in recent results help explain why the cash flow outlook embedded in the DCF is stronger than what the current share price implies. Find out what Gilead Sciences could be worth using our Discounted Cash Flow (DCF) estimate.

The Gilead Sciences Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Gilead Sciences pick up where the valuation puzzle leaves off by spelling out which specific assumptions on future growth, profitability and earnings power would need to hold for the share price to sit meaningfully above or below today's level on the Community page. Each story ties its number to a clear view on how Gilead Sciences' revenue mix, margins and key risks might evolve, giving you something concrete to revisit as fresh information comes through.

The Gilead Sciences community splits between those who see the HIV and oncology engines leaving more room in the valuation and those who think recent enthusiasm already prices in a lot of that story.

Bull case: 7% undervalued

"The main thing that has to go right is that Gilead Sciences converts its expanded HIV PrEP opportunity and emerging oncology launches into sustained uptake that more than offsets pricing pressure and competition…"

Discover why this Narrative puts Gilead Sciences at 7% undervalued.

Bear case: 33% overvalued

"Bear case: Execution risk (M&A integration, oncology competition, pricing pressure) and near-term EPS dilution…"

Explore why this Narrative puts Gilead Sciences at 33% overvalued.

One more Gilead Sciences check that belongs beside the cash flow story

Price and cash generation tell only part of the Gilead Sciences picture, because internal risk checks have raised specific concerns that sit outside the valuation model and call for a closer look. Take a closer look at 2 warning signs before settling on a valuation.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com